Activist Commentary: Cevian Capital, founded in 2002, is an international investment firm acquiring significant ownership positions in publicly listed European companies, where long-term value can be enhanced through active ownership. Cevian Capital is a long-term, hands-on owner of European-listed companies. It is often called a "constructive activist" and is the largest and most experienced dedicated activist investor in Europe. Cevian's strategy is to help its companies become better and more competitive ...

Price Performance SNN carries a Zacks Rank #4 (Sell) at present. Ecolab, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 13.3%. ECL's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 1.7%. Smith & Nephew SNATS (SNN) is likely to witness operational improvements in the future as Cevian Capital, a Swedish investment firm, purchased a 5% stake in the company. Per the Securities and Exchange Commission disclosure, Cevian Capital now ...

Core Viewpoint - Smith+Nephew announces its sponsorship of tennis players at The Championships, Wimbledon 2024, to highlight its advanced Sports Medicine portfolio and commitment to helping individuals recover from injuries and return to their passions [1][9]. Company Overview - Smith+Nephew, founded in 1856 in Hull, UK, operates in over 100 countries and generated annual sales of $5.5 billion in 2023 [4]. - The company focuses on the repair, regeneration, and replacement of soft and hard tissue, aiming to restore individuals' bodies and self-belief through innovative technologies [12]. Sports Medicine Portfolio - Smith+Nephew offers advanced solutions for common tennis injuries, such as rotator cuff tears and meniscus tears, supported by clinical evidence [7]. - The REGENETEN Bioinductive Implant, introduced in 2014, has been used in over 100,000 procedures globally, positively impacting more than 1 million patients annually undergoing rotator cuff surgery [8]. - The FASTFIX Family of meniscal repair solutions has a 30-year legacy, with an 88% mean success rate for all-inside repairs, helping patients recover effectively [8]. Sponsorship Significance - The sponsorship aligns Smith+Nephew with elite athletes, reinforcing its position as a leader in Sports Medicine technology [9]. - The company aims to support athletes in achieving peak performance and recovery through its innovative product offerings [9].

The Good Brigade/DigitalVision via Getty Images Fourth Quarter Results1,2 Revenue Full Year Results1,2 Revenue Operating profit Operating profit margin (%) EPS (cents) Trading profit Trading profit margin (%) EPSA (cents) Medical devices and supplies manufacturer Smith & Nephew (NYSE:SNN) (OTCPK :SNNUF) has had an underwhelming several years, but at its core is a well- positioned business in a business area with premium pricing and long-term growth prospects. My last piece on the name was September 2022's S ...

So in summary, a solid performance in Q1, despite the expected phasing headwinds. Much of the business is performing strongly, OUS recon, Pharma & Extremities, Sports Medicine Joint Repair and negative pressure wound therapy. As we move through Q2, our collective focus remains on addressing the remaining areas of weakness in US Knees and Hips and on driving further operational and financial improvements across the business. So thank you for listening. With that, I'll hand you back to the moderator for Q&A. ...

Smith Nephew Forward looking statements and non-IFRS measures ◊Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office. Mid c -single-digit growth in Orthopaedics and Sports Medicine & ENT, partially offset by expected negative growth in Advanced Wound Bioactives Q1 2024 Revenue Performance Growth by Business Unit* Sports Med & ENT $441m • Underlying revenue growth +2.9%, +2.2% reported Growth by Region* *Growth rates are versus Q1 2023. Business Unit and Regional growth figure ...

Exhibit 99.1 Life Unlimited Smith Nephew Annual Report 2023 Contents Strategic Report | Our performance | IFC | | --- | --- | | Who we are | N | | Chair's statement | ... 4 | | Chief Executive Officer's review | 8 | | Our marketplace | 14 | | Our business model | 16 | | Key Performance Indicators | 18 | | Financial review | 20 | | Creating value through | 26 | | innovation | | | Taking our innovation to market | 34 | | Building a culture of belonging | 46 | | Shaping a healthy and | 52 | | sustainable futur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F INFORMATION FOR SHAREHOLDERS (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 1-14978 Sm (Exact name of Registrant as sp ...

Smith & Nephew plc (NYSE:SNN) Q4 2023 Earnings Conference Call February 27, 2024 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Conference Call Participants Veronika Dubajova - Citi David Adlington - JPMorgan Sam England - Berenberg Jack Reynolds-Clark - RBC Capital Markets Seb Jantet - Liberum Richard Felton - Goldman Sachs Julien Dormois - Jefferies Lisa Clive - Bernstein Sezgi Oezener - HSBC Deepak Nath Good morning and welcome to the ...

Emerging Markets $250m • Record CORI◊placements in US Q4 sales factors Future drivers Q4 sales factors Future drivers 7.8% 7.1% 4.9% Group 6.4% | --- | --- | |-------|-------| | | | | | | 7 * Growth rates are versus Q4 2022 8 FY revenue growth by Business Unit | --- | --- | --- | --- | |--------------------------------------|------------|------------|-----------------| | | FY 2023 $m | FY 2022 $m | Reported growth | | IFRS operating profit | 425 | 450 | (5.4%) | | IFRS operating profit margin | 7.7% | 8.6% ...